Biocon stock surges to fresh 52-week high as restructuring plans fuel investor optimism

 
Biocon rallies on restructuring buzz and Biologics IPO review  
Biocon’s stock has gained momentum after reports confirmed that the company is evaluating strategic options for Biocon Biologics, including a possible $4.5 billion IPO or merger with the parent entity. Chairperson Kiran Mazumdar-Shaw emphasized openness to multiple value-creation routes, sparking investor confidence.  

The stock has delivered over 20 percent returns in the past month, with gains of 28 percent in six months. Analysts note that the restructuring could unlock significant shareholder value, while the company’s strong biosimilars pipeline and partnerships with global players add to long-term growth prospects.  

Important points  

• Biocon hit a fresh 52-week high of ₹422.65 on BSE  
• Company reviewing Biocon Biologics restructuring, IPO, or merger options  
• Near-term trading target: ₹430–₹440; stop-loss around ₹405  
• Stock up 20 percent in one month, 28 percent in six months  
• Institutional demand and biosimilars pipeline seen as key growth drivers  

Sources: Economic Times, LiveMint, ET Now, Stock Price Archive